KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Pacific Biosciences Of California (PACB) Accumulated Depreciation & Amortization (2016 - 2025)

Pacific Biosciences Of California has reported Accumulated Depreciation & Amortization over the past 14 years, most recently at $92.5 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 12.84% year-over-year to $92.5 million; the TTM value through Dec 2025 reached $92.5 million, up 12.84%, while the annual FY2025 figure was $92.5 million, 12.84% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $92.5 million at Pacific Biosciences Of California, up from $81.9 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $92.5 million in Q4 2025 and troughed at $56.3 million in Q4 2021.
  • A 5-year average of $74.1 million and a median of $74.8 million in 2023 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: increased 15.46% in 2022 and later increased 9.56% in 2024.
  • Year by year, Accumulated Depreciation & Amortization stood at $56.3 million in 2021, then rose by 15.46% to $65.0 million in 2022, then rose by 15.09% to $74.8 million in 2023, then grew by 9.56% to $81.9 million in 2024, then increased by 12.84% to $92.5 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for PACB at $92.5 million in Q4 2025, $81.9 million in Q4 2024, and $74.8 million in Q4 2023.